TABLE 3.
Clinical characteristics in people with epilepsy
| Characteristic | Vaccinated, n = 204 a | Unvaccinated, n = 286 | p |
|---|---|---|---|
| Age, years, mean ± SD | 30.9 ± 11.5 | 29.9 ± 10.1 | .93 |
| Course of disease, months, mean ± SD | 96.6 ± 99.8 | 109.3 ± 97.0 | <.0001 |
| Current ASMs, n, mean ± SD | 1.46 ± .80 | 1.83 ± .89 | .63 |
| Drug‐resistant epilepsy, n (%) b | 58 (28.0%) | 146 (50.5%) | .04 |
| Seizure classification, n (%) | |||
| Focal onset | 107 (52.5%) | 138 (48.1%) | .18 |
| Generalized onset | 51 (25.0%) | 73 (25.4%) | .75 |
| Unknown onset | 35 (17.2%) | 57 (19.9%) | <.0001 |
| Unclassified | 11 (5.4%) | 19 (6.6%) | .93 |
| Seizure frequency ranking, n (%) | |||
| Over 1 year seizure‐free | 80 (39.2%) | 65 (22.7%) | <.0001 |
| Once per year | 42 (20.6%) | 35 (12.2%) | .01 |
| Once every 6 months | 17 (8.3%) | 30 (10.5%) | .43 |
| Once every 3 months | 23 (11.3%) | 38 (13.2%) | .52 |
| Once every month | 27 (13.2%) | 70 (24.4%) | .02 |
| Once every week | 12 (5.9%) | 41 (14.3%) | .003 |
| Once every day | 3 (1.5%) | 8 (2.8%) | .331 |
Abbreviation: ASM, antiseizure medication.
a
All participants had the first injection.
b
Excluding newly diagnosed people with epilepsy (course of the disease < 3 months).